NASDAQ: HOOKHookipa Pharma Inc Stock
$0.81-0.04 (-4.71%)
Updated Apr 25, 2024
HOOK Price
$0.81
Fair Value Price
N/A
Market Cap
$79.75M
52 Week Low
$0.41
52 Week High
$2.05
P/E
-0.94x
P/B
0.89x
P/S
3.38x
PEG
N/A
Dividend Yield
N/A
Revenue
$20.13M
Earnings
-$81.58M
Gross Margin
100%
Operating Margin
-401.88%
Profit Margin
-405.3%
Debt to Equity
0.8
Operating Cash Flow
-$58M
Beta
1.27
Next Earnings
Jun 7, 2024
Ex-Dividend
N/A
Next Dividend
N/A
HOOK Overview
HOOKIPA Pharma Inc., a clinical stage biopharmaceutical company, develops immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company's lead infectious disease product candidate is HB-101, which is in a randomized double-blinded Phase II clinical trial in patients awaiting kidney transplantation from cytomegalovirus-positive donors. Its lead oncology product candidates are HB-201 and HB-202 that are in Phase I/II clinical trial for the treatment of human papillomavirus 16-positive cancers. The company's preclinical stage products include HB-300 program for prostate cancer; and HB-700 for targeting mutated KRAS in pancreatic, colorectal, and lung cancer. HOOKIPA Pharma Inc. has a collaboration with Gilead Sciences, Inc. to collaborate on preclinical research programs to evaluate potential vaccine products using or incorporating its replicating and non-replicating technology platforms for the treatment, cure, diagnosis, or prevention of Hepatitis B Virus. The company was incorporated in 2011 and is headquartered in New York, New York.
Zen Score
–
Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how HOOK scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
HOOK is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
HOOK is good value based on its book value relative to its share price (0.89x), compared to the US Biotechnology industry average (5.8x)
P/B vs Industry Valuation
HOOK is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more HOOK due diligence checks available for Premium users.
Be the first to know about important HOOK news, forecast changes, insider trades & much more!
HOOK News
Valuation
HOOK price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.94x
Industry
15.41x
Market
40.97x
HOOK price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.89x
Industry
5.8x
HOOK is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
HOOK's financial health
Profit margin
Revenue
$7.4M
Net Income
-$24.8M
Profit Margin
-335.1%
HOOK's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
HOOK's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$161.3M
Liabilities
$71.5M
Debt to equity
0.8
HOOK's short-term assets ($147.12M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
HOOK's short-term assets ($147.12M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
HOOK's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
HOOK's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$11.2M
Investing
-$422.0k
Financing
$21.2M
HOOK's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
HOOK vs Biotech Stocks
Hookipa Pharma Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.